Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan List

Showing results (41-50 of 72) with videos related to

Pageof 8
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|August 14, 2016
Myelodysplastic Syndromes in Adolescent Young Adults: One Institution's ExperienceJoanna Grabska, Bijal Shah, Damon Reed, et al.
Leukemia|June 23, 2020
Characterization of myelodysplastic syndromes (MDS) with T-cell large granular lymphocyte proliferations (LGL)Rami S Komrokji, Najla Al Ali, David Sallman, et al.
The New England Journal of Medicine|February 11, 2005
Efficacy of lenalidomide in myelodysplastic syndromesAlan List, Sandy Kurtin, Denise J Roe, et al.
Blood Cancer Journal|November 28, 2017
ASXL1 frameshift mutations drive inferior outcomes in CMML without negative impact in MDSDavid A Sallman, Rami Komrokji, Thomas Cluzeau, et al.
Blood|April 29, 2009
Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndromeAzra Raza, Naomi Galili, Scott Smith, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 12, 2020
Decoding Bone Marrow Fibrosis in Myelodysplastic SyndromesMegan Melody, Najla Al Ali, Ling Zhang, et al.
Blood|December 8, 2009
Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropeniaRekha Pal, Sara A Monaghan, Andrea Cortese Hassett, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 7, 2020
Defining Acute Myeloid Leukemia Ontogeny in Older PatientsMegan Melody, Andrew Kuykendall, David Sallman, et al.
Haematologica|October 7, 2017
Pro-inflammatory proteins S100A9 and tumor necrosis factor-α suppress erythropoietin elaboration in myelodysplastic syndromesThomas Cluzeau, Kathy L McGraw, Brittany Irvine, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 19, 2014
Pretransplantation 5-azacitidine in high-risk myelodysplastic syndromeTaiga Nishihori, Janelle Perkins, Asmita Mishra, et al.
Pageof 8

Showing results (41-50 of 72) with videos related to

Sort By:
Pageof 8
Clinical Lymphoma, Myeloma & Leukemia|August 14, 2016
Myelodysplastic Syndromes in Adolescent Young Adults: One Institution's ExperienceJoanna Grabska, Bijal Shah, Damon Reed, et al.
Leukemia|June 23, 2020
Characterization of myelodysplastic syndromes (MDS) with T-cell large granular lymphocyte proliferations (LGL)Rami S Komrokji, Najla Al Ali, David Sallman, et al.
The New England Journal of Medicine|February 11, 2005
Efficacy of lenalidomide in myelodysplastic syndromesAlan List, Sandy Kurtin, Denise J Roe, et al.
Blood Cancer Journal|November 28, 2017
ASXL1 frameshift mutations drive inferior outcomes in CMML without negative impact in MDSDavid A Sallman, Rami Komrokji, Thomas Cluzeau, et al.
Blood|April 29, 2009
Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndromeAzra Raza, Naomi Galili, Scott Smith, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 12, 2020
Decoding Bone Marrow Fibrosis in Myelodysplastic SyndromesMegan Melody, Najla Al Ali, Ling Zhang, et al.
Blood|December 8, 2009
Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropeniaRekha Pal, Sara A Monaghan, Andrea Cortese Hassett, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 7, 2020
Defining Acute Myeloid Leukemia Ontogeny in Older PatientsMegan Melody, Andrew Kuykendall, David Sallman, et al.
Haematologica|October 7, 2017
Pro-inflammatory proteins S100A9 and tumor necrosis factor-α suppress erythropoietin elaboration in myelodysplastic syndromesThomas Cluzeau, Kathy L McGraw, Brittany Irvine, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 19, 2014
Pretransplantation 5-azacitidine in high-risk myelodysplastic syndromeTaiga Nishihori, Janelle Perkins, Asmita Mishra, et al.
Pageof 8